Anthera Pharmaceuticals, Inc. (ANTH)
OTCMKTS: ANTH · Delayed Price · USD
0.0001
0.00 (0.00%)
Aug 29, 2024, 4:00 PM EDT - Market closed
Company Description
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs.
It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy.
The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Anthera Pharmaceuticals, Inc.
Country | United States |
Founded | 2004 |
IPO Date | Mar 1, 2010 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 21 |
CEO | John Thompson |
Contact Details
Address: The Pennzoil Building, Suite 1300 Houston, Texas 77002 United States | |
Phone | 410 350 1839 |
Website | anthera.com |
Stock Details
Ticker Symbol | ANTH |
Exchange | OTCMKTS |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001316175 |
CUSIP Number | 03674U300 |
ISIN Number | US03674U3005 |
Employer ID | 20-1852016 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
John Craig Thompson | Chief Executive Officer and Director |
Paul F. Truex M.B.A. | Executive Chairman |
May Liu | Senior Vice President of Finance and Administration and Principal Accounting Officer |
Dr. Paul Adams Ph.D. | Senior Vice President of Global Regulatory Affairs and Compliance |
Joshua Caldwell | Chief Liquidating Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jul 30, 2018 | 15-12B | Securities registration termination |
Jul 26, 2018 | EFFECT | Notice of Effectiveness |
Jul 26, 2018 | EFFECT | Notice of Effectiveness |
Jul 26, 2018 | EFFECT | Notice of Effectiveness |
Jul 26, 2018 | EFFECT | Notice of Effectiveness |
Jul 26, 2018 | EFFECT | Notice of Effectiveness |
Jul 26, 2018 | EFFECT | Notice of Effectiveness |
Jul 26, 2018 | EFFECT | Notice of Effectiveness |
Jul 20, 2018 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
Jul 20, 2018 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |